Binge Eating Disorder Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The binge eating disorder market was valued at USD 0.81 Billion in 2024 driven by increasing awareness, advancements in treatment options, and the rising prevalence of the disorder across the 8 major markets. It is expected to grow at a CAGR of 6.00% during the forecast period 2025-2034 and attain a market value of USD 1.45 Billion by 2034.
Binge Eating Disorder Market Overview
Binge eating disorder (BED) is characterized by excessive eating within a short period, without engaging in purging behaviors such as vomiting. It can result in obesity, heart disease, and emotional problems. BED is the result of a combination of genetic, psychological, and environmental factors such as genetics, lack of self-confidence, and societal influences. Binge episodes can be exacerbated by stress and negative emotions.
Genetic factors, hormonal imbalances, and dopamine are all factors that influence the development and severity of the disorder. Mental health problems such as depression, anxiety, and previous trauma can lead to episodes of binge eating, along with emotional stressors. Societal expectations, limited eating habits, and genetic predisposition for eating disorders may elevate the chances of developing one.
Binge eating disorder treatment typically includes a mix of counseling, drugs, and adjustments in lifestyle. Cognitive behavioral therapy (CBT) is successful in handling triggers, while drugs such as lisdexamfetamine and antidepressants aid in diminishing cravings and balancing mood.
Binge Eating Disorder Market Growth Drivers
Increasing Prevalence of Binge Eating Disorder Spurs Market Growth
The rising occurrence of binge eating disorder is driving the growth of the market as awareness of mental health increases. As per the Eating Recovery Center’s eating disorder statistics for 2024, 28.8 million Americans, or 9% of the U.S. population, will experience an eating disorder at some point in their lives. Each year, 10,200 deaths occur due to eating disorders, resulting in one death every 52 minutes. Urbanization, inactive lifestyles, and high-stress levels lead to a rise in BED cases, particularly in developed areas.
Growing Awareness and Diagnosis to Meet Rising Binge Eating Disorder Market Demand
Efforts in public health campaigns and education have contributed to raising awareness of BED as a significant mental health condition. During the National Eating Disorders Awareness Week in February 2024, Monte Nido & Affiliates conducted an educative session on binge eating disorder. As a leading eating disorder treatment provider in the United States, they offer vital resources and expanded virtual treatment programs in 28 states. Their specialty program addresses core features of shame, guilt, and self-blame associated with binge eating disorder, encouraging individuals to seek help for mental health issues without fear of judgment has led to an increase in early diagnoses. Healthcare providers have improved their skills in recognizing BED, resulting in an increased need for treatment choices.
Binge Eating Disorder Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advances in Treatments
Progress in treatments is leading to a rise in the need for medication-based therapies that focus on the neurological and psychological components of BED. Continued studies on novel drugs are expanding the range of treatment options, as pharmaceutical companies are funding clinical trials to create better treatments with reduced side effects. This is helping to tailor treatment plans to individuals and maintain market growth for treatments of BED.
Rising Use of Non-Invasive Therapies to Boost Binge Eating Disorder Market Value
Non-intrusive treatments like cognitive behavioral therapy (CBT) are gaining popularity for addressing BED. These treatments concentrate on altering eating habits and emotional cues without requiring invasive techniques. Treatment plans also incorporate group therapy, family counseling, and nutritional education among others.
Rising Focus on Mental Health in Corporate Wellness Programs
The increasing focus on mental health in company wellness initiatives is resulting in the inclusion of resources for the condition. Businesses are broadening their benefits packages to incorporate therapy, counseling, and stress management initiatives to tackle the consequences of untreated binge eating disorders. Educational workshops on eating disorders are being integrated to increase awareness and encourage early intervention.
Use of Digital Therapeutics
Digital therapeutics are influencing the treatment of BED by providing accessible resources such as mobile apps and online platforms for self-directed programs and cognitive behavioral therapy. These electronic tools enable people to monitor their symptoms in real-time and get remote assistance via telehealth services, especially helping younger patients and those in disadvantaged regions. The demand for digital therapeutics in treating BED is rising due to their cost efficiency and effectiveness.
Binge Eating Disorder Market Segmentation
The EMR’s report titled “Binge Eating Disorder Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Share Based on Route of Administration to Witness Substantial Growth
Based on the route of administration, the market is divided into oral, parenteral, and others. The most frequent administration is through oral administration, where drugs such as lisdexamfetamine and antidepressants can be easily included in daily schedules. Oral medications allow for flexibility in dosage and self-administration, increasing accessibility and affordability for long-term treatment.
Binge Eating Disorder Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market because of the high prevalence of the disorder and the availability of advanced treatment options, along with extensive awareness initiatives and strong healthcare facilities encouraging treatment acceptance. Drugs such as lisdexamfetamine and treatments like CBT are frequently utilized, supported by insurance and government efforts.
There has been a significant increase in market growth in the EU-4 countries and the United Kingdom due to the rising awareness of eating disorders as serious health issues, leading to more investment in mental health services and a higher demand for treatments. The market in Japan and India is rapidly expanding driven by greater awareness, diagnosis rates,h ealthcare infrastructure enhancements, lifestyle modifications, urbanization, and stress.
Leading Players in the Binge Eating Disorder Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals is a biopharmaceutical company dedicated to creating new treatments for central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. In July 2023, they started enrolling participants in the MGH Phase 2 'STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the treatment of binge-eating disorder in July 2023.
Chronos Therapeutics Limited
Chronos Therapeutics Ltd is a UK-based pharmaceutical company focused on developing drugs for neurodegenerative diseases. They are a major player in the binge eating disorder market, utilizing Orexin -1 Antagonist research for effective treatment with minimal side effects.
Pyramid Healthcare Inc.
Pyramid Healthcare offers a range of healthcare services in the United States, including residential and outpatient treatment, dual diagnosis, mental health, transitional housing, and specialty programs for substance abuse, mental health, autism, and eating disorders.
Eli Lilly and Company
Eli Lilly and Company in Indianapolis, Indiana is a healthcare company developing medications for various health conditions. The FDA approved Lilly's Zepbound (tirzepatide) in November 2023 for chronic weight management, providing a new treatment option for those struggling with obesity or being overweight with weight-related medical issues.
Other players in the market are Takeda Pharmaceutical Company Limited, VIVUS LLC, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics Inc., Jazz Pharmaceuticals Inc., and Novo Nordisk A/S.
Key Questions Answered in the Binge Eating Disorder Market Report
Binge Eating Disorder Market Overview
Binge eating disorder (BED) is characterized by excessive eating within a short period, without engaging in purging behaviors such as vomiting. It can result in obesity, heart disease, and emotional problems. BED is the result of a combination of genetic, psychological, and environmental factors such as genetics, lack of self-confidence, and societal influences. Binge episodes can be exacerbated by stress and negative emotions.
Genetic factors, hormonal imbalances, and dopamine are all factors that influence the development and severity of the disorder. Mental health problems such as depression, anxiety, and previous trauma can lead to episodes of binge eating, along with emotional stressors. Societal expectations, limited eating habits, and genetic predisposition for eating disorders may elevate the chances of developing one.
Binge eating disorder treatment typically includes a mix of counseling, drugs, and adjustments in lifestyle. Cognitive behavioral therapy (CBT) is successful in handling triggers, while drugs such as lisdexamfetamine and antidepressants aid in diminishing cravings and balancing mood.
Binge Eating Disorder Market Growth Drivers
Increasing Prevalence of Binge Eating Disorder Spurs Market Growth
The rising occurrence of binge eating disorder is driving the growth of the market as awareness of mental health increases. As per the Eating Recovery Center’s eating disorder statistics for 2024, 28.8 million Americans, or 9% of the U.S. population, will experience an eating disorder at some point in their lives. Each year, 10,200 deaths occur due to eating disorders, resulting in one death every 52 minutes. Urbanization, inactive lifestyles, and high-stress levels lead to a rise in BED cases, particularly in developed areas.
Growing Awareness and Diagnosis to Meet Rising Binge Eating Disorder Market Demand
Efforts in public health campaigns and education have contributed to raising awareness of BED as a significant mental health condition. During the National Eating Disorders Awareness Week in February 2024, Monte Nido & Affiliates conducted an educative session on binge eating disorder. As a leading eating disorder treatment provider in the United States, they offer vital resources and expanded virtual treatment programs in 28 states. Their specialty program addresses core features of shame, guilt, and self-blame associated with binge eating disorder, encouraging individuals to seek help for mental health issues without fear of judgment has led to an increase in early diagnoses. Healthcare providers have improved their skills in recognizing BED, resulting in an increased need for treatment choices.
Binge Eating Disorder Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advances in Treatments
Progress in treatments is leading to a rise in the need for medication-based therapies that focus on the neurological and psychological components of BED. Continued studies on novel drugs are expanding the range of treatment options, as pharmaceutical companies are funding clinical trials to create better treatments with reduced side effects. This is helping to tailor treatment plans to individuals and maintain market growth for treatments of BED.
Rising Use of Non-Invasive Therapies to Boost Binge Eating Disorder Market Value
Non-intrusive treatments like cognitive behavioral therapy (CBT) are gaining popularity for addressing BED. These treatments concentrate on altering eating habits and emotional cues without requiring invasive techniques. Treatment plans also incorporate group therapy, family counseling, and nutritional education among others.
Rising Focus on Mental Health in Corporate Wellness Programs
The increasing focus on mental health in company wellness initiatives is resulting in the inclusion of resources for the condition. Businesses are broadening their benefits packages to incorporate therapy, counseling, and stress management initiatives to tackle the consequences of untreated binge eating disorders. Educational workshops on eating disorders are being integrated to increase awareness and encourage early intervention.
Use of Digital Therapeutics
Digital therapeutics are influencing the treatment of BED by providing accessible resources such as mobile apps and online platforms for self-directed programs and cognitive behavioral therapy. These electronic tools enable people to monitor their symptoms in real-time and get remote assistance via telehealth services, especially helping younger patients and those in disadvantaged regions. The demand for digital therapeutics in treating BED is rising due to their cost efficiency and effectiveness.
Binge Eating Disorder Market Segmentation
The EMR’s report titled “Binge Eating Disorder Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Antidepressant
- Anticonvulsant
- Anti-obesity Medication
- Others
- Oral
- Parenteral
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- United States
- EU-4 and the United Kingdom
- Japan
- India
Market Share Based on Route of Administration to Witness Substantial Growth
Based on the route of administration, the market is divided into oral, parenteral, and others. The most frequent administration is through oral administration, where drugs such as lisdexamfetamine and antidepressants can be easily included in daily schedules. Oral medications allow for flexibility in dosage and self-administration, increasing accessibility and affordability for long-term treatment.
Binge Eating Disorder Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market because of the high prevalence of the disorder and the availability of advanced treatment options, along with extensive awareness initiatives and strong healthcare facilities encouraging treatment acceptance. Drugs such as lisdexamfetamine and treatments like CBT are frequently utilized, supported by insurance and government efforts.
There has been a significant increase in market growth in the EU-4 countries and the United Kingdom due to the rising awareness of eating disorders as serious health issues, leading to more investment in mental health services and a higher demand for treatments. The market in Japan and India is rapidly expanding driven by greater awareness, diagnosis rates,h ealthcare infrastructure enhancements, lifestyle modifications, urbanization, and stress.
Leading Players in the Binge Eating Disorder Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals is a biopharmaceutical company dedicated to creating new treatments for central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. In July 2023, they started enrolling participants in the MGH Phase 2 'STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the treatment of binge-eating disorder in July 2023.
Chronos Therapeutics Limited
Chronos Therapeutics Ltd is a UK-based pharmaceutical company focused on developing drugs for neurodegenerative diseases. They are a major player in the binge eating disorder market, utilizing Orexin -1 Antagonist research for effective treatment with minimal side effects.
Pyramid Healthcare Inc.
Pyramid Healthcare offers a range of healthcare services in the United States, including residential and outpatient treatment, dual diagnosis, mental health, transitional housing, and specialty programs for substance abuse, mental health, autism, and eating disorders.
Eli Lilly and Company
Eli Lilly and Company in Indianapolis, Indiana is a healthcare company developing medications for various health conditions. The FDA approved Lilly's Zepbound (tirzepatide) in November 2023 for chronic weight management, providing a new treatment option for those struggling with obesity or being overweight with weight-related medical issues.
Other players in the market are Takeda Pharmaceutical Company Limited, VIVUS LLC, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics Inc., Jazz Pharmaceuticals Inc., and Novo Nordisk A/S.
Key Questions Answered in the Binge Eating Disorder Market Report
- What was the binge eating disorder market value in 2024?
- What is the binge eating disorder market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on drug class?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on distribution channels?
- What are the major factors aiding the binge eating disorder market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the binge eating disorder market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Binge Eating Disorder Market Overview: 8 Major Market
- 3.1 Binge Eating Disorder Market Historical Value (2018-2024)
- 3.2 Binge Eating Disorder Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Binge Eating Disorder: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Binge Eating Disorder Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Type Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Binge Eating Disorder Market Landscape: 8 Major Market*
- 8.1 Binge Eating Disorder Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Binge Eating Disorder Market: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Route of Administration
- 9 Binge Eating Disorder Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Binge Eating Disorder: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Binge Eating Disorder Market Segmentation: 8 Major Markets
- 12.1 Binge Eating Disorder Market by Drug Class
- 12.1.1 Market Overview
- 12.1.2 Antidepressant
- 12.1.3 Anticonvulsant
- 12.1.4 Anti-obesity Medication
- 12.1.5 Others
- 12.2 Binge Eating Disorder Market by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Others
- 12.3 Binge Eating Disorder Market by Distribution Channel
- 12.3.1 Market Overview
- 12.3.2 Hospital Pharmacy
- 12.3.3 Retail Pharmacy
- 12.3.4 Online Pharmacy
- 12.3.5 Others
- 12.4 Binge Eating Disorder Market by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Binge Eating Disorder Market (218-2034)
- 13.1 United States Binge Eating Disorder Market Historical Value (2018-2024)
- 13.2 United States Binge Eating Disorder Market Forecast Value (2025-2034)
- 13.3 United States Binge Eating Disorder Market by Drug Class
- 13.3.1 Market Overview
- 13.3.2 Antidepressant
- 13.3.3 Anticonvulsant
- 13.3.4 Anti-obesity Medication
- 13.3.5 Others
- 13.4 United States Binge Eating Disorder Market by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Others
- 13.5 United States Binge Eating Disorder Market by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacy
- 13.5.3 Retail Pharmacy
- 13.5.4 Online Pharmacy
- 13.5.5 Others
- 14 EU-4 and United Kingdom Binge Eating Disorder Market (218-2034)
- 14.1 EU-4 and United Kingdom Binge Eating Disorder Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Binge Eating Disorder Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Binge Eating Disorder Market by Drug Class
- 14.3.1 Market Overview
- 14.3.2 Antidepressant
- 14.3.3 Anticonvulsant
- 14.3.4 Anti-obesity Medication
- 14.3.5 Others
- 14.4 EU-4 and United Kingdom Binge Eating Disorder Market by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Binge Eating Disorder Market by Distribution Channel
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacy
- 14.5.3 Retail Pharmacy
- 14.5.4 Online Pharmacy
- 14.5.5 Others
- 15 Japan Binge Eating Disorder Market
- 15.1 Japan Binge Eating Disorder Market Historical Value (2018-2024)
- 15.2 Japan Binge Eating Disorder Market Forecast Value (2025-2034)
- 15.3 Japan Binge Eating Disorder Market by Drug Class
- 15.3.1 Market Overview
- 15.3.2 Antidepressant
- 15.3.3 Anticonvulsant
- 15.3.4 Anti-obesity Medication
- 15.3.5 Others
- 15.4 Japan Binge Eating Disorder Market by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Others
- 15.5 Japan Binge Eating Disorder Market by Distribution Channel
- 15.5.1 Market Overview
- 15.5.2 Hospital Pharmacy
- 15.5.3 Retail Pharmacy
- 15.5.4 Online Pharmacy
- 15.5.5 Others
- 16 India Binge Eating Disorder Market
- 16.1 India Binge Eating Disorder Market Historical Value (2018-2024)
- 16.2 India Binge Eating Disorder Market Forecast Value (2025-2034)
- 16.3 India Binge Eating Disorder Market by Drug Class
- 16.3.1 Market Overview
- 16.3.2 Antidepressant
- 16.3.3 Anticonvulsant
- 16.3.4 Anti-obesity Medication
- 16.3.5 Others
- 16.4 India Binge Eating Disorder Market by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.4.4 Others
- 16.5 India Binge Eating Disorder Market by Distribution Channel
- 16.5.1 Market Overview
- 16.5.2 Hospital Pharmacy
- 16.5.3 Retail Pharmacy
- 16.5.4 Online Pharmacy
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Tonix Pharmaceuticals Holding Corp.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 Takeda Pharmaceutical Company Limited
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Chronos Therapeutics Limited
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Pyramid Healthcare Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 VIVUS LLC.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Sunovion Pharmaceuticals Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 H. Lundbeck A/S
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 Orexigen Therapeutics, Inc
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 23.10 Novo Nordisk A/S
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Developments
- 23.10.5 Certifications
- 23.11 Eli Lily and Company
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Developments
- 23.11.5 Certifications
- 23.12 Jazz Pharmaceuticals Inc.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Company News and Developments
- 23.12.5 Certifications
- 24 Binge Eating Disorder Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
